Moderna's stock price plummeted 20% in early trading! Sales of two flagship products were disappointing, leading to a significant cut in the annual revenue forecast.

① The American vaccine manufacturer Moderna expects revenue for 2025 to be between 1.5 billion and 2.5 billion USD due to a slowdown in demand for its two main products, which is significantly lower than the previously expected 2.5 billion to 3.5 billion USD; ② Moderna's stock price fell 20% due to the lowered revenue expectations, with its CEO stating that the adjustment reflects increased competition in the COVID-19 vaccine market, delayed infrastructure development, and a decline in vaccination rates.

cls.cnJan 13 23:01

Trending Stocks Today | Phio Pharmaceuticals Surges 323.96%

January 13th - US stocks trending in regular trading hours.Gainers: $Phio Pharmaceuticals(PHIO.US)$ surges 323.96% to $7.17 with a turnover of $1.3 billion. $Salarius Pharmaceuticals(SLRX.US)$

Futu News6minutes ago

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge

Benzinga6minutes ago

Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel

MT Newswires16minutes ago

A Mixed Bag of Factors Influencing Moderna's Stock This Month

Yahoo Finance23minutes ago

The Top and Bottom Contributors to S&P 500's Q4 EPS Growth

Seeking Alpha24minutes ago